Excivion Presents at Seventeenth UK Hepacivirus and Flavivirus Meeting - 17th-19th May 2019
Excivion Ltd. Announces the development of a novel point-of-care diagnostic to
facilitate the safe use of dengue vaccines in the field
- Excivion has developed an unique proprietary diagnostic to identify
dengue-naive subjects who should be spared dengue vaccination -
CAMBRIDGE, UK – (May 17, 2019) – Excivion Ltd (www.excivion.com) “Excivion”, a developer of novel vaccines for the prevention of emerging pandemic infectious diseases, today announced that it has developed a point-of-care diagnostic test with performance characteristics suitable, once licensed, to identify subjects who are dengue-naive and who should be spared dengue vaccination, in order to avoid the risk of priming for severe dengue. The current practice, required by the FDA, is that a laboratory-based test should be used for this purpose. However, the logistics of a laboratory-based test complicate the process of screening and there is general agreement that point-of-care is a better solution for the purpose
(Luo et al PMID: 30664935,
Commenting on the new development, Peter Laing, CEO of Excivion, said, "There are a number of point-of-care tests in existence for historic dengue, but these have limited sensitivity and have been hampered by the emergence of Zika as a pandemic disease - the tests being generally not capable of reliably distinguishing prior Zika from dengue. In this instance we re-invented the point-of-care dengue test from the ground up, making it more sensitive and specific than licensed point-of-care tests, and better in these respects than many lab-based tests. We also made the test 'scaleable' to be manufacturable in the millions. In order to scientifically validate the test we made extensive use of plaque neutralisation assay which is the current 'gold standard', albeit requiring culture of live virus. The next step for us is to achieve licensing of the test as a companion diagnostic for dengue vaccines. We are currently seeking partners and philanthropic funding to bring this about. We further anticipate that Zika vaccines in development may require the use of the test as a companion diagnostic, in order to avoid priming for severe dengue in dengue-naive subjects."
The diagnostic has a number of proprietary innovations and exploits Excivion's unique glycan-cloaking technology which places an 'invisibility cloak' over the major cross-reactive site of the dengue and Zika antigens, such that cross-reactive antibodies (that would otherwise result in mis-diagnosis) can not be detected in the test which is highly specific for dengue antibodies. The compositions of matter and novel test architecture are protected by two PCT stage patent applications, the first of which (on the cloaked antigens), having entered the National Phase, is now pending in thirteen territories world-wide. Both of these applications have received very favourable PCT examination reports.
Peter Laing went on to say "The generous support and validation of the UK Government who are funding this work via a contract under the Small Business Research Initiative (SBRI) from the UK’s innovation agency, Innovate UK is gratefully acknowledged. Without their help we would never have been able to develop the test.”
Excivion is a UK-based biotechnology company developing solutions to the present and emerging healthcare needs of society that are sustainable and affordable by healthcare systems in the face of competing priorities imposed by an ageing population and the emergence of pandemic diseases. Excivion is producing novel vaccines that can be used to prevent emerging pandemic infectious diseases and to prevent and treat chronic diseases of ageing. Vaccines, historically, have proven the most cost-effective solution to disease prevention, but also have a formidable potential to treat diseases once they have arisen. Excivion is in the vanguard of a new pharmaceutical model for this changing world in which vaccines feature globally in both disease-prevention and in the treatment of chronic diseases.
About Innovate UK
Innovate UK is the UK’s Innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. www.innovateuk.gov.uk
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected benefits of NGS cancer panels, the ability to accurately determine the heritable factors increasing the risk of cancer, permitting tailored treatment, screening and prevention of cancer in patients, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Source: Excivion Ltd.